<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156104</url>
  </required_header>
  <id_info>
    <org_study_id>P05926</org_study_id>
    <secondary_id>Hera</secondary_id>
    <secondary_id>41023</secondary_id>
    <nct_id>NCT00156104</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by
      Positive symptoms (symptoms that should not be there, inability to think clearly, to
      distinguish reality from fantasy i.e., hearing voices) and Negative symptoms (a reduction or
      absence of normal behaviors or emotions, i.e., unable to manage emotions, make decisions and
      relate to others). Other symptoms include reduced ability to recall and learn new
      information, difficulty with problem solving, or maintaining productive employment. The
      symptoms of schizophrenia may be due to an imbalance in chemicals in the brain, primarily
      dopamine and serotonin, which enables brain cells to communicate with each other.

      Asenapine is an investigational drug that may help to correct the inbalance in dopamine and
      serotonin. This is a 6-week trial to test the efficacy and safety of asenapine, compared with
      placebo, using an active comparator agent (haloperidol) in the treatment of patients with an
      acute exacerbation of schizophrenia. Patients who complete the 6-week trial will have the
      option of continuing in an additional one year extension trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2005</start_date>
  <completion_date type="Actual">September 16, 2006</completion_date>
  <primary_completion_date type="Actual">August 18, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in schizophrenia (change in total PANSS score) from baseline to endpoint (LOCF/MMRM)</measure>
    <time_frame>Primary outcome measured weekly for 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other dimensions of schizophrenia (positive, negative, disorganized thought, hostility/excitement, anxiety/depression, and general psychopathology) CGI-S; CGI-I</measure>
    <time_frame>At weekly intervals throughout the 6-week trial.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognition and cognitive functioning</measure>
    <time_frame>Baseline and Endpoint ( Day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDSS</measure>
    <time_frame>Days 21 and 42(Endpoint).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal thinking ( ISST modified)</measure>
    <time_frame>Days 14 and 42 (Endpoint)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and patient functionality (QLS; Q-LES-Q ;PETIT0; Physical exam; Pregnancy test</measure>
    <time_frame>Baseline and Day 42(Endpoint)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readiness to discharge</measure>
    <time_frame>At weekly intervals during the 6-week trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPS ( AIMS; BARS; SARS)</measure>
    <time_frame>At weekly intervals during the 6-week triaL</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Labs; Vital Signs; Weight and girth; ECG</measure>
    <time_frame>Days 14; 28 and 42 (Endpoint)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine 5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine 10 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol 4m mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>5 mg BID</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>10 mg BID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>4 mg BID</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo arm</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently suffering from an acute exacerbation of schizophrenia. Caregiver required.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable medical condition. Have any other pyschiatric disorder
             other than schizophrenia as a primary diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010 Apr;30(2):106-15. doi: 10.1097/JCP.0b013e3181d35d6b.</citation>
    <PMID>20520283</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

